Carcinoid encephalopathy: A single entity or a spectrum of different disorders?
Lapeire
Lore D
LD
Department of Medical Oncology, University Hospital Ghent, Gent, Belgium.
Tansens
Anneleen
A
Lemmens
Gilbert M D
GM
Van Belle
Simon J
SJ
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000150:complications / Q000556:secondary*; D002276:Carcinoid Tumor / Q000503:physiopathology / Q000556:secondary* / Q000628:therapy; D003131:Combined Modality Therapy; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage; D007414:Intestinal Neoplasms / Q000473:pathology* / Q000503:physiopathology / Q000628:therapy; D008297:Male; D008303:Malignant Carcinoid Syndrome / Q000188:drug therapy / Q000503:physiopathology*; D001523:Mental Disorders / Q000188:drug therapy / Q000209:etiology*; D015282:Octreotide / Q000008:administration & dosage; D010456:Peptides, Cyclic / Q000008:administration & dosage; D011878:Radiotherapy; D018967:Risperidone / Q000627:therapeutic use; D012702:Serotonin Antagonists / Q000627:therapeutic use; D013004:Somatostatin / Q000008:administration & dosage / Q000031:analogs & derivatives
D016898:Interferon-alpha; D010456:Peptides, Cyclic; D012702:Serotonin Antagonists; C060347:lanreotide; D013004:Somatostatin; D018967:Risperidone; D015282:Octreotide